Table 3. Association between the prognostic role of mRNA expression of NK receptor ligands and lymph-node status.
| RFS | OS | ||||
|---|---|---|---|---|---|
| Ligand | Lymph node negative | Lymph node positive | Lymph node negative | Lymph node positive | |
| NK-activating ligands | AICL HR (95%CI) p-value |
0.89 (0.73–1.08) 0.24 |
0.74 (0.60–0.91) 0.028 |
1.52 (1.05–2.20) 0.069 |
0.44 (0.30–0.66) 0.0011 |
| B7-1 HR (95%CI) p-value |
1.36 (0.89–2.07) 0.18 |
0.71 (0.52–0.96) 0.064 |
0.40 (0.15–1.04) 0.12 |
0.48 (0.28–0.84) 0.021 |
|
| B7-2 HR (95%CI) p-value |
1.16 (0.96–1.40) 0.18 |
1.19 (0.97–1.44) 0.12 |
0.78 (0.54–1.13) 0.26 |
0.83 (0.55–1.24) 0.39 |
|
| BAT3 HR (95%CI) p-value |
1.44 (1.21–1.70) 0.00099 |
0.81 (0.67–1.00) 0.081 |
1.32 (0.87–2.02) 0.26 |
1.50 (1.02–2.21) 0.073 |
|
| CD27 HR (95%CI) p-value |
0.73 (0.62–0.87) 0.0018 |
0.7 (0.57–0.85) 0.0024 |
0.62 (0.42–0.9) 0.045 |
0.46 (0.31–0.68) 0.0011 |
|
| CD48 HR (95%CI) p-value |
0.87 (0.74–1.03) 0.18 |
0.79 (0.65–0.96) 0.058 |
0.71 (0.49–1.04) 0.16 |
0.47 (0.32–0.70) 0.0011 |
|
| CD58 HR (95%CI) p-value |
0.79 (0.64-0.96) 0.057 |
1.2 (1-1.44) 0.081 |
0.58 (0.39-0.86) 0.044 |
1.36 (0.9-2.07) 0.18 |
|
| CD70 HR (95%CI) p-value |
1.16 (0.96–1.40) 0.18 |
1.30 (1.07–1.59) 0.032 |
1.25 (0.86–1.81) 0.27 |
1.66 (1.10–2.49) 0.034 |
|
| CD72 HR (95%CI) p-value |
0.86 (0.71–1.04) 0.18 |
1.09 (0.87–1.37) 0.47 |
0.82 (0.57–1.19) 0.30 |
0.52 (0.33–0.81) 0.012 |
|
| KMT2E HR (95%CI) p-value |
0.7 (0.44–1.1) 0.18 |
1.15 (0.89–1.48) 0.30 |
0.19 (0.06–0.59) 0.043 |
1.28 (0.76–2.16) 0.39 |
|
| MICA HR (95%CI) p-value |
1.12 (0.93–1.34) 0.24 |
0.83 (0.67–1.03) 0.12 |
1.35 (0.91–2.02) 0.24 |
1.19 (0.81–1.76) 0.39 |
|
| MICB HR (95%CI) p-value |
0.88 (0.74–1.06) 0.22 |
0.66 (0.54–0.81) 0.00065 |
0.77 (0.50–1.20) 0.27 |
0.49 (0.33–0.72) 0.0018 |
|
| NECL2 HR (95%CI) p-value |
0.85 (0.72–1.01) 0.13 |
0.81 (0.66–1.00) 0.081 |
0.57 (0.40–0.83) 0.043 |
0.71 (0.46–1.10) 0.16 |
|
| SLAMF6 HR (95%CI) p-value |
0.64 (0.43–0.94) 0.057 |
0.70 (0.54–0.90) 0.028 |
1.72 (0.68–4.37) 0.27 |
0.80 (0.46–1.39) 0.44 |
|
| SLAMF7 HR (95%CI) p-value |
0.58 (0.35–0.94) 0.057 |
0.70 (0.51–0.96) 0.066 |
0.72 (0.28–1.84) 0.49 |
0.33 (0.17–0.65) 0.0045 |
|
| TNFSF9 HR (95%CI) p-value |
0.85 (0.72–1.01) 0.12 |
1.09 (0.90–1.33) 0.39 |
0.57 (0.39–0.84) 0.043 |
0.76 (0.50–1.15) 0.22 |
|
| ULBP1 HR (95%CI) p-value |
0.85 (0.71–1.03) 0.18 |
1.22 (0.97–1.55) 0.12 |
0.62 (0.42–0.91) 0.046 |
1.34 (0.91–1.98) 0.17 |
|
| ULBP2 HR (95%CI) p-value |
2.14 (1.45–3.17) 0.001 |
1.81 (1.40–2.35) 0.00015 |
2.75 (1.10–6.89) 0.069 |
1.78 (1.05–3.03) 0.062 |
|
| ULBP3 HR (95%CI) p-value |
1.38 (0.89–2.13) 0.18 |
1.25 (0.95–1.63) 0.12 |
1.99 (0.66–6.00) 0.27 |
2.55 (1.49–4.34) 0.0023 |
|
| ULBP4 HR (95%CI) p-value |
0.72 (0.47–1.10) 0.18 |
1.28 (0.96–1.72) 0.12 |
0.44 (0.16–1.23) 0.20 |
1.62 (0.90–2.93) 0.15 |
|
| VIM HR (95%CI) p-value |
0.9 (0.76–1.06) 0.22 |
0.83 (0.67–1.03) 0.12 |
1.3 (0.89–1.88) 0.26 |
0.53 (0.35–0.79) 0.0064 |
|
| NK-activating and inhibitory ligands | HLA-C HR (95%CI) p-value |
0.77 (0.64–0.92) 0.022 |
0.82 (0.66 -1.02) 0.10 |
0.60 (0.41–0.87) 0.044 |
0.54 (0.37–0.81) 0.0088 |
| HLA-E HR (95%CI) p-value |
0.72 (0.61–0.86) 0.0012 |
0.84 (0.68–1.04) 0.12 |
0.74 (0.51–1.07) 0.20 |
0.58 (0.39–0.86) 0.017 |
|
| NECL5 HR (95%CI) p-value |
0.78 (0.65–0.94) 0.032 |
1.26 (0.99–1.59) 0.092 |
1.27 (0.85–1.88) 0.27 |
0.62 (0.38–0.99) 0.074 |
|
| NECTIN2 HR (95%CI) p-value |
0.71 (0.60–0.85) 0.001 |
0.65 (0.53–0.79) 0.00019 |
0.57 (0.37–0.88) 0.045 |
0.70 (0.45–1.07) 0.15 |
|
| NK-inhibitory ligands | CEACAM1 HR (95%CI) p-value |
0.82 (0.69–0.97) 0.057 |
0.83 (0.68–1.01) 0.10 |
1.34 (0.89–2.02) 0.26 |
0.62 (0.41–0.95) 0.062 |
| CLEC2D HR (95%CI) p-value |
0.85 (0.57–1.28) 0.44 |
0.71 (0.55–0.92) 0.032 |
0.60 (0.23–1.59) 0.30 |
1.21 (0.69–2.15) 0.51 |
|
| COL3A1 HR (95%CI) p-value |
0.9 (0.76–1.07) 0.24 |
0.78 (0.64–0.95) 0.044 |
0.79 (0.54–1.17) 0.27 |
0.65 (0.44–0.96) 0.062 |
|
| HLA-A HR (95%CI) p-value |
0.81 (0.68–0.97) 0.057 |
0.75 (0.61–0.93) 0.032 |
0.70 (0.47–1.03) 0.16 |
0.71 (0.47–1.08) 0.15 |
|
| HLA-B HR (95%CI) p-value |
0.79 (0.65–0.94) 0.034 |
0.79 (0.63–0.98) 0.068 |
0.61 (0.41–0.90) 0.046 |
0.66 (0.44–0.99) 0.074 |
|
| PDL1 HR (95%CI) p-value |
0.51 (0.34–0.77) 0.0052 |
0.75 (0.58–0.99) 0.081 |
0.55 (0.22–1.36) 0.26 |
0.45 (0.26–0.79) 0.013 |
|
| PDL2 HR (95%CI) p-value |
0.87 (0.73–1.03) 0.18 |
0.83 (0.65–1.05) 0.13 |
1.62 (1.10–2.39) 0.048 |
0.72 (0.49–1.06) 0.15 |
|